SUMMARY Cartilage glycosaminoglycans (GAGs) were measured by a spectrophotometric assay in synovial fluid obtained from 30 normal bovine hock joints and 15 osteoarthritic human knee joints. Results were compared with those obtained by radioimmunoassay (RIA). The spectrophotometric method (dimethylmethylene blue (DMB) assay) was found to be simple, safe, and sufficiently reproducible to be of potential value for serial measurement of sulphated GAGs in arthritic joint fluids. The nature of the proteoglycans present in normal bovine and osteoarthritic human synovial fluid was examined by gel chromatography. Whereas normal bovine synovial fluid contained only small molecular weight proteoglycans, osteoarthritic human synovial fluid contained aggregated proteoglycans and predominantly high molecular weight proteoglycan subunits.
Glycosaminoglycan assays have been used extensively in the past to measure proteoglycans in vitro, but with the exception of urine they have proved unsatisfactory for measurement of proteoglycans in biological fluids, mainly because they are subject to interference by other polyanions.- ' 6 In particular, such assays have been unsuitable for the determina- Dimethylmethylene blue dye reagent (2.5 ml) was then added and the absorbance at 525 nm was read after 15 s in a Cecil CE 292 digital ultraviolet spectrophotometer. The DMB reagent was prepared by adding 3-04 g of glycine, 2.37 g of NaCl, and 16 mg of 1,9-dimethylmethylene blue to 1 litre of deionized water. The pH was adjusted to 3 0 with hydrochloric acid and the reagent was stored in a brown bottle.
The DMB assay was calibrated with shark chondroitin sulphate and suitable solvent blanks. GEL 
CHROMATOGRAPHY
The hydrodynamic size distribution of the proteoglycans in normal bovine and osteoarthritic human synovial fluids was determined by gel chromatography on columns (67x 1 cm) of Sepharose CL-2B. Samples consisting of 1 ml of synovial fluid and the proteinase inhibitors, 1,10-phenanthroline (1 mM), iodoacetic acid (1 mM), and phenylmethylsulphonyl fluoride (1 mM) were applied to the column and chromatographed at 22°C and 6 ml/h. Fractions Chondroitin sulphate added (,ug) Proteoglycan added (,ug) Fig. 1 (a 10 [tg/ml for the RIA and 20 tg/ml for the DMB assay. In synovial fluid the within assay coefficient of variation was 5.3% (n=10) for the DMB assay and 13-8% (n=5) for the RIA. The between assay coefficient of variation was 11*2% (n=3) for the DMB assay and 29-2% (n=3) for the RIA. Thus the DMB assay was more reproducible and the RIA twice as sensitive.
Increasing quantities of proteoglycan were added to undiluted synovial fluid, and the recovery determined by each assay procedure is shown in Fig. 1 fig/ml, n= 15 ). With the RIA the mean concentration of proteoglycans was 122 jg/ml of synovial fluid (SE 10 jg/ml, n=15). The scatter of the results obtained with each method is shown in Fig. 2 . The correlation coefficient was 0-51 (0-10>p>005, Student's t test).
SIZE DISTRIBUTION OF THE PROTEOGLYCANS IN SYNOVIAL FLUID
Normal bovine synovial fluids were found to contain mainly small proteoglycan molecules (Fig. 3a) . In contrast, osteoarthritic human synovial fluids contained a significant proportion of aggregated proteoglycan in addition to monomeric proteoglycans of diverse molecular weight (Fig. 3b) . The difference in the position of the peaks indicates that the proteoglycans of varying hydrodynamic size differ with respect to their sulphated GAG content. In normal bovine synovial fluid the proteoglycans of higher molecular weight (corresponding to effluent volumes 38-48 ml) are richer in sulphated GAG than those of lower molecular weight (corresponding to effluent volumes 49-58 ml). In human synovial fluid from patients with osteoarthritis it can be seen from the data in Fig. 3b that the aggregated proteoglycans (corresponding to effluent volumes 20-25 ml) have a lower sulphated GAG content than the large and small proteoglycan monomers. The presence of proteoglycan aggregates in the human synovial fluid indicates that some of the proteoglycan molecules are bound to hyaluronic 300- Fig. 3 Size distribution of the cartilage degradation products in (a) normal bovine synovialfluid and (b) osteoarthritic human knee joint synovialfluid.
acid and suggests that these molecules still possess a sufficiently sensitive for measurement of cartilage functionally intact binding domain. degradation products in synovial fluid. Samples of synovial fluid were assayed directly with the RIA Discussion whereas previous digestion with papain was necessary for the DMB assay. The reproducibility of the The DMB assay and RIA were both found to be assays was found to be satisfactory for the DMB Gel chromatography of normal bovine synovial fluid showed the presence of predominantly small proteoglycan molecules. No proteoglycan aggregates were detected. These findings are unlikely to be due to proteolysis during storage or chromatography since consistent results were obtained when fresh specimens were chromatographed immediately in the presence of various proteinase inhibitors. The remote possibility of rapid postmortem catabolism, however, cannot be excluded. Whether the size distribution of the proteoglycans in normal human synovial fluid is similar is not yet known.
In contrast, a significant proportion of the proteoglycans present in osteoarthritic synovial fluid were found to be aggregated and most of the monomers present were of higher molecular weight. This distribution is in agreement with that found by Gysen et al and closely resembles the size distribution of the proteoglycans which can be extracted from human articular cartilage with high concentrations of salt."' Although the mechanism governing the release of proteoglycans from osteoarthritic cartilage is still a matter of conjecture, the presence in the synovial fluid of proteoglycans with a functionally intact hyaluronic acid binding region suggests that at least a subset of proteoglycans may be released from cartilage without enzymatic cleavage of this region.
In summary, the modified DMB assay has been shown to be suitable for measuring glycosaminoglycans in synovial fluid. In addition to being sufficiently sensitive, specific, and reproducible the method is simple, safe, and inexpensive. The DMB assay expands the range of methods now available for measuring cartilage degradation products in synovial fluid. These techniques are likely to prove increasingly useful for monitoring disease progression and the effects of various therapeutic strategies. In combination with other lines of inquiry they are also likely to provide further insight into the mechanisms responsible for cartilage resorption in arthritic diseases. 
